Ford Motor Firm (NYSE:F) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of remains unchanged to 11.92 with about 23.62 Million shares have changed hands in this session. BMW Group, Daimler AG, Ford Motor Firm (F) and Volkswagen Group with Audi and Porsche have inked a memorandum of understanding to create the highest-powered charging network in Europe. The goal is the quick buildup of a sizable number of stations to enable long-range travel for battery electric vehicle drivers.
The projected ultra-fast charging network with power levels up to 350 kilowatt will be importantly faster than the most powerful charging system deployed . The buildup is planned to start in 2017. An initial target of about 400 sites in Europe is planned.
By 2020, consumers should have access to thousands of high-powered charging points. The goal is to enable long-distance travel through open-network charging stations along highways and major thoroughfares, which has not been feasible for most battery electric vehicle drivers to date. The stock is going forward its fifty-two week low with 11.94% and lagging behind from its 52-week high price with -14.20%.
Same, the positive performance for the quarter recorded as -3.84% and for the year was -11.02%, while the YTD performance remained at -9.50%. F has Average True Range for 14 days of 0.22.
Shares of Cerecor Inc. (NASDAQ:CERC) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -7.63% to close at $4.72. Cerecor Inc. (NASDAQ:CERC) reported that top-line clinical results from its major depressive disorder (MDD) Phase 2 clinical trial (Clin301-203) of adjunctive treatment of CERC-301, an oral, NR2B specific, NMDA receptor antagonist.
Overall, the trial failed to demonstrate efficacy on the primary endpoint for mean improvement in Bech-6, a subset of the Hamilton Depression Scale (HDRS-17), averaged over days 2 and 4 post dose. However, the study showed signals for the CERC-301 20 mg dose group at Day 2, at pre-specified secondary endpoints, indicating a potentially clinically-meaningful effect, though not statistically important, on the Bech-6 and HDRS-17. The stock is going forward its fifty-two week low with 143.30% and lagging behind from its 52-week high price with -15.71%. CERC last month stock price volatility remained 12.81%.